Business · 1 sources covering this

Mankind Pharma Q2 Review: Jefferies, Kotak Retain Buy After Strong Earnings. Check Target Prices

Jefferies maintained its Buy' rating on Mankind Pharma but lowered its target price to Rs 2,900 from Rs 3,220, citing a stronger growth outlook and easing integration challenges.

Share:WhatsApp X Reddit Facebook LinkedIn

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

NDTVCenter·1h ago
Mankind Pharma Q2 Review: Jefferies, Kotak Retain Buy After Strong Earnings. Check Target Prices
Jefferies maintained its Buy' rating on Mankind Pharma but lowered its target price to Rs 2,900 from Rs 3,220, citing a stronger growth outlook and easing integration challenges.
Read at NDTV →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://hindustansphere.com/embed/cluster/20809ed30bbd39c613981da569e2a85b75ba8fa4"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="Mankind Pharma Q2 Review: Jefferies, Kotak Retain Buy After Strong Earnings. Check Target Prices"></iframe>

Mankind Pharma Q2 Review: Jefferies, Kotak Retain Buy After Strong Earnings. Check Target Prices

How 1 sources are covering this

Mankind Pharma Q2 Review: Jefferies, Kotak Retain Buy After Strong Earnings. Check Target Prices

More from Business

South Africa Vs Australia 3rd Test Live Streaming: When And Where To Watch In India

IMD Weather Alert! What Andhra, Telangana, Gujarat, West Bengal, UP, Bihar, Keralam residents must know before going out

ITC Hotels Shares Extend Rally; Jump 6% After Q2 Profit Surges More Than 50%

Nifty F&O Expiry Today: 22,700 Emerges As Key Battleground, Sees Heavy OI Build-Up; 23,000 Call OI In Focus

Reader

Trust & legal

Across the network